Patents by Inventor Gokhan MUTLU

Gokhan MUTLU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA
    Publication number: 20220040207
    Abstract: Disclosed herein is a class of molecules termed remodilins that inhibit serum response factor (SRF). By inhibiting SRF, a number of downstream pathways can be targeted. The remodilins can be used to treat glaucoma, inhibit tumor cell growth, inhibit tumor metastasis, inhibit hypoxia-induced response, and/or reduce cellular metabolism.
    Type: Application
    Filed: April 2, 2020
    Publication date: February 10, 2022
    Applicants: The University of Chicago, The United States of America as Represented by the Secretary Department of Health and Human Services, President and Fellows of Harvard College, IIT Research Institute, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Julian SOLWAY, Nickolai DULIN, Marsha ROSNER, Gokhan MUTLU, Diane LUCI, David MALONEY, Chan Young PARK, Jeffrey FREDBERG, David MCCORMICK, Ramaswamy KRISHNAN
  • COMPOSITIONS AND METHODS FOR ACTIVATING NRF2-DEPENDENT GENE EXPRESSION
    Publication number: 20220031656
    Abstract: Embodiments are directed to a series of novel small molecule activators of NRF2 dependent gene expression that are evaluated in an effort to develop therapeutic methods against diseases with deregulated KEAP1-NRF2 signaling.
    Type: Application
    Filed: October 14, 2019
    Publication date: February 3, 2022
    Applicant: The University of Chicago
    Inventors: Raymond MOELLERING, John COUKOS, Gihoon LEE, Jae Won CHANG, Gokhan MUTLU